Skip to main content
Top
Published in: BMC Nephrology 1/2020

Open Access 01-12-2020 | Liver Function Test | Research article

Baseline liver function tests and full blood count indices and their association with progression of chronic kidney disease and renal outcomes in Aboriginal and Torres Strait Islander people: the eGFR follow- up study

Authors: Sandawana William Majoni, Federica Barzi, Wendy Hoy, Richard J. MacIsaac, Alan Cass, Louise Maple-Brown, Jaquelyne T. Hughes

Published in: BMC Nephrology | Issue 1/2020

Login to get access

Abstract

Background

Determination of risks for chronic kidney disease (CKD) progression could improve strategies to reduce progression to ESKD. The eGFR Study recruited a cohort of adult Aboriginal and Torres Strait Islander people (Indigenous Australians) from Northern Queensland, Northern Territory and Western Australia, aiming to address the heavy CKD burden experienced within these communities.

Methods

Using data from the eGFR study, we explored the association of baseline liver function tests (LFTs) (alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), bilirubin and albumin) and full blood count (FBC) indices (white blood cell and red blood cell counts and haemoglobin) with annual eGFR decline and renal outcomes (first of 30% decline in eGFR with a follow-up eGFR < 60 mL/min/1.73 m2, initiation of renal replacement therapy, or renal death). Comparisons of baseline variables across eGFR categories were calculated using analysis of variance and logistic regression as appropriate. Linear and multivariable regression models were used to estimate the annual change in eGFR for changes in FBC indices and LFTs. Cox proportional hazard models were used to estimate the hazard ratio for developing renal outcome for changes in baseline FBC indices and LFTs.

Results

Of 547 participants, 540 had at least one baseline measure of LFTs and FBC indices. The mean age was 46.1 (14.7) years and 63.6% were female. The median follow-up was 3.1 (IQR 2.8–3.6) years. Annual decline in eGFR was associated with low serum albumin (p < 0.001) and haemoglobin (p = 0.007). After adjustment for age, gender, urine albumin/creatinine ratio, diabetes, BMI, CRP, WHR, alcohol consumption, cholesterol and triglycerides, low serum albumin (p < 0.001), haemoglobin (p = 0.012) and bilirubin (p = 0.011) were associated with annual decline in eGFR.
Renal outcomes were inversely associated with serum albumin (p < 0.001), bilirubin (p = 0.012) and haemoglobin (p < 0.001) and directly with GGT (p = 0.007) and ALP (p < 0.001). Other FBC indices and LFTs were not associated with annual decline in eGFR or renal outcomes.

Conclusions

GGT, ALP, bilirubin, albumin and haemoglobin independently associate with renal outcomes. Contrary to findings from other studies, no association was found between renal outcomes and other FBC indices. These findings may help focus strategies to prevent disease progression in this high-risk population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hoy WE, Mott SA, Mc Donald SP. An expanded nationwide view of chronic kidney disease in Aboriginal Australians. Nephrology (Carlton, Vic). 2016;21(11):916–22.CrossRef Hoy WE, Mott SA, Mc Donald SP. An expanded nationwide view of chronic kidney disease in Aboriginal Australians. Nephrology (Carlton, Vic). 2016;21(11):916–22.CrossRef
2.
go back to reference Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, Rahman M, Lash JP, Townsend RR, Ojo A, et al. Inflammation and progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2016;11(9):1546–56.PubMedPubMedCentralCrossRef Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, Rahman M, Lash JP, Townsend RR, Ojo A, et al. Inflammation and progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2016;11(9):1546–56.PubMedPubMedCentralCrossRef
3.
go back to reference Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7(12):1938–46.PubMedPubMedCentralCrossRef Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7(12):1938–46.PubMedPubMedCentralCrossRef
4.
go back to reference Barr ELM, Barzi F, Hughes JT, Jerums G, Hoy WE, O'Dea K, Jones GRD, Lawton PD, Brown ADH, Thomas M, et al. High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in indigenous Australians with diabetes: the eGFR follow-up study. Diabetes Care. 2018;41(4):739–47.PubMedCrossRef Barr ELM, Barzi F, Hughes JT, Jerums G, Hoy WE, O'Dea K, Jones GRD, Lawton PD, Brown ADH, Thomas M, et al. High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in indigenous Australians with diabetes: the eGFR follow-up study. Diabetes Care. 2018;41(4):739–47.PubMedCrossRef
5.
go back to reference Fan F, Jia J, Li J, Huo Y, Zhang Y. White blood cell count predicts the odds of kidney function decline in a Chinese community-based population. BMC Nephrol. 2017;18(1):190.PubMedPubMedCentralCrossRef Fan F, Jia J, Li J, Huo Y, Zhang Y. White blood cell count predicts the odds of kidney function decline in a Chinese community-based population. BMC Nephrol. 2017;18(1):190.PubMedPubMedCentralCrossRef
6.
go back to reference Bowe B, Xie Y, Xian H, Li T, Al-Aly Z. Association between monocyte count and risk of incident CKD and progression to ESRD. Clin J Am Soc Nephrol. 2017;12(4):603–13.PubMedPubMedCentralCrossRef Bowe B, Xie Y, Xian H, Li T, Al-Aly Z. Association between monocyte count and risk of incident CKD and progression to ESRD. Clin J Am Soc Nephrol. 2017;12(4):603–13.PubMedPubMedCentralCrossRef
7.
go back to reference Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Katafuchi E, Seki M, Tsuda S, Nakano T, Tsuruya K, Kitazono T. High neutrophil/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. Ren Fail. 2019;41(1):238–43.PubMedPubMedCentralCrossRef Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Katafuchi E, Seki M, Tsuda S, Nakano T, Tsuruya K, Kitazono T. High neutrophil/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. Ren Fail. 2019;41(1):238–43.PubMedPubMedCentralCrossRef
8.
go back to reference Yuan Q, Wang J, Peng Z, Zhou Q, Xiao X, Xie Y, Wang W, Huang L, Tang W, Sun D, et al. Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). J Transl Med. 2019;17(1):86.PubMedPubMedCentralCrossRef Yuan Q, Wang J, Peng Z, Zhou Q, Xiao X, Xie Y, Wang W, Huang L, Tang W, Sun D, et al. Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). J Transl Med. 2019;17(1):86.PubMedPubMedCentralCrossRef
9.
go back to reference Hughes JT, Barzi F, Hoy WE, Jones GRD, Rathnayake G, Majoni SW, Thomas MAB, Sinha A, Cass A, MacIsaac RJ, et al. Bilirubin concentration is positively associated with haemoglobin concentration and inversely associated with albumin to creatinine ratio among indigenous Australians: eGFR study. Clin Biochem. 2017;50(18):1040–7.PubMedCrossRef Hughes JT, Barzi F, Hoy WE, Jones GRD, Rathnayake G, Majoni SW, Thomas MAB, Sinha A, Cass A, MacIsaac RJ, et al. Bilirubin concentration is positively associated with haemoglobin concentration and inversely associated with albumin to creatinine ratio among indigenous Australians: eGFR study. Clin Biochem. 2017;50(18):1040–7.PubMedCrossRef
10.
go back to reference Maple-Brown LJ, Hughes JT, Lawton PD, Jones GR, Ellis AG, Drabsch K, Brown AD, Cass A, Hoy WE, MacIsaac RJ, et al. Accurate assessment of kidney function in indigenous Australians: the estimated GFR study. Am J Kidney Dis. 2012;60(4):680–2.PubMedCrossRef Maple-Brown LJ, Hughes JT, Lawton PD, Jones GR, Ellis AG, Drabsch K, Brown AD, Cass A, Hoy WE, MacIsaac RJ, et al. Accurate assessment of kidney function in indigenous Australians: the estimated GFR study. Am J Kidney Dis. 2012;60(4):680–2.PubMedCrossRef
11.
go back to reference Maple-Brown LJ, Lawton PD, Hughes JT, Sharma SK, Jones GR, Ellis AG, Hoy W, Cass A, Macisaac RJ, Sinha AK, et al. Study protocol--accurate assessment of kidney function in indigenous Australians: aims and methods of the eGFR study. BMC Public Health. 2010;10:80.PubMedPubMedCentralCrossRef Maple-Brown LJ, Lawton PD, Hughes JT, Sharma SK, Jones GR, Ellis AG, Hoy W, Cass A, Macisaac RJ, Sinha AK, et al. Study protocol--accurate assessment of kidney function in indigenous Australians: aims and methods of the eGFR study. BMC Public Health. 2010;10:80.PubMedPubMedCentralCrossRef
12.
go back to reference Maple-Brown LJ, Ekinci EI, Hughes JT, Chatfield M, Lawton PD, Jones GR, Ellis AG, Sinha A, Cass A, Hoy WE, et al. Performance of formulas for estimating glomerular filtration rate in indigenous Australians with and without type 2 diabetes: the eGFR study. Diabetic Med. 2014;31(7):829–38.PubMedCrossRef Maple-Brown LJ, Ekinci EI, Hughes JT, Chatfield M, Lawton PD, Jones GR, Ellis AG, Sinha A, Cass A, Hoy WE, et al. Performance of formulas for estimating glomerular filtration rate in indigenous Australians with and without type 2 diabetes: the eGFR study. Diabetic Med. 2014;31(7):829–38.PubMedCrossRef
13.
go back to reference Maple-Brown LJ, Hughes JT, Ritte R, Barzi F, Hoy WE, Lawton PD, Jones GRD, Death E, Simmonds A, Sinha AK, et al. Progression of kidney disease in indigenous Australians: the eGFR follow-up study. Clin J Am Soc Nephrol. 2016;11(6):993–1004.PubMedPubMedCentralCrossRef Maple-Brown LJ, Hughes JT, Ritte R, Barzi F, Hoy WE, Lawton PD, Jones GRD, Death E, Simmonds A, Sinha AK, et al. Progression of kidney disease in indigenous Australians: the eGFR follow-up study. Clin J Am Soc Nephrol. 2016;11(6):993–1004.PubMedPubMedCentralCrossRef
14.
go back to reference Barzi F, Jones GRD, Hughes JT, Lawton PD, Hoy W, O'Dea K, Jerums G, MacIsaac RJ, Cass A, Maple-Brown LJ. Trajectories of eGFR decline over a four year period in an indigenous Australian population at high risk of CKD-the eGFR follow up study. Clin Biochem. 2018;53:58–64.PubMedCrossRef Barzi F, Jones GRD, Hughes JT, Lawton PD, Hoy W, O'Dea K, Jerums G, MacIsaac RJ, Cass A, Maple-Brown LJ. Trajectories of eGFR decline over a four year period in an indigenous Australian population at high risk of CKD-the eGFR follow up study. Clin Biochem. 2018;53:58–64.PubMedCrossRef
15.
go back to reference Ekinci EI, Hughes JT, Chatfield MD, Lawton PD, Jones GR, Ellis AG, Cass A, Thomas M, MacIsaac RJ, O'Dea K, et al. Hyperfiltration in indigenous Australians with and without diabetes. Nephrol Dialysis Transplantation. 2015;30(11):1877–84.CrossRef Ekinci EI, Hughes JT, Chatfield MD, Lawton PD, Jones GR, Ellis AG, Cass A, Thomas M, MacIsaac RJ, O'Dea K, et al. Hyperfiltration in indigenous Australians with and without diabetes. Nephrol Dialysis Transplantation. 2015;30(11):1877–84.CrossRef
16.
go back to reference Barr EL, Barzi F, Hughes JT, Jerums G, O'Dea K, Brown AD, Ekinci EI, Jones GR, Lawton PD, Sinha A, et al. Contribution of cardiometabolic risk factors to estimated glomerular filtration rate decline in Indigenous Australians with and without albuminuria - the eGFR Follow-up Study. Nephrology (Carlton, Vic). 2018;23(7):682–9.CrossRef Barr EL, Barzi F, Hughes JT, Jerums G, O'Dea K, Brown AD, Ekinci EI, Jones GR, Lawton PD, Sinha A, et al. Contribution of cardiometabolic risk factors to estimated glomerular filtration rate decline in Indigenous Australians with and without albuminuria - the eGFR Follow-up Study. Nephrology (Carlton, Vic). 2018;23(7):682–9.CrossRef
17.
go back to reference Park S, Kim DH, Hwang JH, Kim Y-C, Kim JH, Lim CS, Kim YS, Yang SH, Lee JP. Elevated bilirubin levels are associated with a better renal prognosis and ameliorate kidney fibrosis. PLoS One. 2017;12(2):e0172434.PubMedPubMedCentralCrossRef Park S, Kim DH, Hwang JH, Kim Y-C, Kim JH, Lim CS, Kim YS, Yang SH, Lee JP. Elevated bilirubin levels are associated with a better renal prognosis and ameliorate kidney fibrosis. PLoS One. 2017;12(2):e0172434.PubMedPubMedCentralCrossRef
18.
go back to reference Sakoh T, Nakayama M, Tanaka S, Yoshitomi R, Ura Y, Nishimoto H, Fukui A, Shikuwa Y, Tsuruya K, Kitazono T. Association of serum total bilirubin with renal outcome in Japanese patients with stages 3&#x2013;5 chronic kidney disease. Metab Clin Exp. 2015;64(9):1096–102.PubMedCrossRef Sakoh T, Nakayama M, Tanaka S, Yoshitomi R, Ura Y, Nishimoto H, Fukui A, Shikuwa Y, Tsuruya K, Kitazono T. Association of serum total bilirubin with renal outcome in Japanese patients with stages 3&#x2013;5 chronic kidney disease. Metab Clin Exp. 2015;64(9):1096–102.PubMedCrossRef
19.
go back to reference Yang TL, Lin YC, Lin YC, Huang CY, Chen HH, Wu MS. Total Bilirubin in Prognosis for Mortality in End&#x2010;Stage Renal Disease Patients on Peritoneal Dialysis Therapy. J Am Heart Assoc. 2017;6(12):e007507.PubMedPubMedCentralCrossRef Yang TL, Lin YC, Lin YC, Huang CY, Chen HH, Wu MS. Total Bilirubin in Prognosis for Mortality in End&#x2010;Stage Renal Disease Patients on Peritoneal Dialysis Therapy. J Am Heart Assoc. 2017;6(12):e007507.PubMedPubMedCentralCrossRef
20.
go back to reference Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol. 2014;307(2):F123–36.PubMedCrossRef Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol. 2014;307(2):F123–36.PubMedCrossRef
21.
go back to reference Li M, Li X, Liu Y, Liu X, Song Y, Zhao J, Mohan C, Wu T, Peng A, Qin L. Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia. Clin Chim Acta. 2018;486:156–61.PubMedCrossRef Li M, Li X, Liu Y, Liu X, Song Y, Zhao J, Mohan C, Wu T, Peng A, Qin L. Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia. Clin Chim Acta. 2018;486:156–61.PubMedCrossRef
22.
go back to reference Liu Y, Li M, Song Y, Liu X, Zhao J, Deng B, Peng A, Qin L. Association of serum bilirubin with renal outcomes in Han Chinese patients with chronic kidney disease. Clin Chim Acta. 2018;480:9–16.PubMedCrossRef Liu Y, Li M, Song Y, Liu X, Zhao J, Deng B, Peng A, Qin L. Association of serum bilirubin with renal outcomes in Han Chinese patients with chronic kidney disease. Clin Chim Acta. 2018;480:9–16.PubMedCrossRef
23.
go back to reference Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S. A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: need for new reference ranges. Int J Appl Basic Med Res. 2015;5(1):31–5.PubMedPubMedCentralCrossRef Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S. A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: need for new reference ranges. Int J Appl Basic Med Res. 2015;5(1):31–5.PubMedPubMedCentralCrossRef
24.
go back to reference Sette LHBC, EPD AL. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review. Clinics (Sao Paulo). 2014;69(4):271–8.CrossRef Sette LHBC, EPD AL. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review. Clinics (Sao Paulo). 2014;69(4):271–8.CrossRef
25.
go back to reference Caravaca-Fontán F, Azevedo L, Bayo M, Gonzales-Candia B, Luna E, Caravaca F. High levels of both serum gamma-glutamyl transferase and alkaline phosphatase are independent preictors of mortality in patients with stage 4-5 chronic kidney disease. Nefrologia. 2017;37(3):267–75.PubMedCrossRef Caravaca-Fontán F, Azevedo L, Bayo M, Gonzales-Candia B, Luna E, Caravaca F. High levels of both serum gamma-glutamyl transferase and alkaline phosphatase are independent preictors of mortality in patients with stage 4-5 chronic kidney disease. Nefrologia. 2017;37(3):267–75.PubMedCrossRef
26.
go back to reference Chen T, Ren Y, Gao Y, Tian H. Serum gamma-Glutamyl Transferase and ferritin synergistically associated with the rate of chronic kidney disease. Dis Markers. 2017;2017:9765259.PubMedPubMedCentral Chen T, Ren Y, Gao Y, Tian H. Serum gamma-Glutamyl Transferase and ferritin synergistically associated with the rate of chronic kidney disease. Dis Markers. 2017;2017:9765259.PubMedPubMedCentral
27.
go back to reference Noborisaka Y, Ishizaki M, Yamazaki M, Honda R, Yamada Y. Elevated serum gamma-Glutamyltransferase (GGT) activity and the development of chronic kidney disease (CKD) in cigarette smokers. Nephrourol Mon. 2013;5(5):967–73.PubMedPubMedCentralCrossRef Noborisaka Y, Ishizaki M, Yamazaki M, Honda R, Yamada Y. Elevated serum gamma-Glutamyltransferase (GGT) activity and the development of chronic kidney disease (CKD) in cigarette smokers. Nephrourol Mon. 2013;5(5):967–73.PubMedPubMedCentralCrossRef
28.
go back to reference Lee DY, Han K, Yu JH, Park S, Heo JI, Seo JA, Kim NH, Yoo HJ, Kim SG, Kim SM, et al. Gamma-glutamyl transferase variability can predict the development of end-stage of renal disease: a nationwide population-based study. Sci Rep. 2020;10(1):11668.PubMedPubMedCentralCrossRef Lee DY, Han K, Yu JH, Park S, Heo JI, Seo JA, Kim NH, Yoo HJ, Kim SG, Kim SM, et al. Gamma-glutamyl transferase variability can predict the development of end-stage of renal disease: a nationwide population-based study. Sci Rep. 2020;10(1):11668.PubMedPubMedCentralCrossRef
29.
go back to reference Kunutsor SK, Laukkanen JA. Gamma-glutamyltransferase and risk of chronic kidney disease: a prospective cohort study. Clin Chim Acta. 2017;473:39–44.PubMedCrossRef Kunutsor SK, Laukkanen JA. Gamma-glutamyltransferase and risk of chronic kidney disease: a prospective cohort study. Clin Chim Acta. 2017;473:39–44.PubMedCrossRef
30.
go back to reference Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S. Management of mineral and bone disorder after kidney transplantation. Curr Opinion Nephrol Hypertension. 2004;21(4):389–403.CrossRef Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S. Management of mineral and bone disorder after kidney transplantation. Curr Opinion Nephrol Hypertension. 2004;21(4):389–403.CrossRef
31.
go back to reference Taliercio JJ, Schold JD, Simon JF, Arrigain S, Tang A, Saab G, Nally JV Jr, Navaneethan SD. Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J kidney Dis. 2013;62(4):703–10.PubMedPubMedCentralCrossRef Taliercio JJ, Schold JD, Simon JF, Arrigain S, Tang A, Saab G, Nally JV Jr, Navaneethan SD. Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J kidney Dis. 2013;62(4):703–10.PubMedPubMedCentralCrossRef
32.
go back to reference Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dialysis Transplant. 2010;25(9):3003–11.CrossRef Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dialysis Transplant. 2010;25(9):3003–11.CrossRef
33.
go back to reference Haller C. Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations. Kidney Blood Pressure Res. 2005;28(5–6):307–10.CrossRef Haller C. Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations. Kidney Blood Pressure Res. 2005;28(5–6):307–10.CrossRef
34.
go back to reference Alves FC, Sun J, Qureshi AR, Dai L, Snaedal S, Bárány P, Heimbürger O, Lindholm B, Stenvinkel P. The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. PLoS One. 2018;13(1):e0190410.PubMedPubMedCentralCrossRef Alves FC, Sun J, Qureshi AR, Dai L, Snaedal S, Bárány P, Heimbürger O, Lindholm B, Stenvinkel P. The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. PLoS One. 2018;13(1):e0190410.PubMedPubMedCentralCrossRef
35.
go back to reference Lang J, Katz R, Ix JH, Gutierrez OM, Peralta CA, Parikh CR, Satterfield S, Petrovic S, Devarajan P, Bennett M, et al. Association of serum albumin levels with kidney function decline and incident chronic kidney disease in elders. Nephrology Dialysis Transplantation. 2017;33(6):986–92.PubMedCentralCrossRef Lang J, Katz R, Ix JH, Gutierrez OM, Peralta CA, Parikh CR, Satterfield S, Petrovic S, Devarajan P, Bennett M, et al. Association of serum albumin levels with kidney function decline and incident chronic kidney disease in elders. Nephrology Dialysis Transplantation. 2017;33(6):986–92.PubMedCentralCrossRef
36.
go back to reference Zhang J, Zhang R, Wang Y, Li H, Han Q, Wu Y, Wang T, Liu F. The level of serum albumin is associated with renal prognosis in patients with diabetic nephropathy. J Diabetes Res. 2019;2019:7825804.PubMedPubMedCentral Zhang J, Zhang R, Wang Y, Li H, Han Q, Wu Y, Wang T, Liu F. The level of serum albumin is associated with renal prognosis in patients with diabetic nephropathy. J Diabetes Res. 2019;2019:7825804.PubMedPubMedCentral
37.
go back to reference Arai Y, Kanda E, Iimori S, Naito S, Noda Y, Sasaki S, Sohara E, Okado T, Rai T, Uchida S. Low white blood cell count is independently associated with chronic kidney disease progression in the elderly: the CKD-ROUTE study. Clin Exp Nephrol. 2018;22(2):291–8.PubMedCrossRef Arai Y, Kanda E, Iimori S, Naito S, Noda Y, Sasaki S, Sohara E, Okado T, Rai T, Uchida S. Low white blood cell count is independently associated with chronic kidney disease progression in the elderly: the CKD-ROUTE study. Clin Exp Nephrol. 2018;22(2):291–8.PubMedCrossRef
38.
go back to reference Tsai Y-C, Hung C-C, Kuo M-C, Tsai J-C, Yeh S-M, Hwang S-J, Chiu Y-W, Kuo H-T, Chang J-M, Chen H-C. Association of hsCRP, white blood cell count and ferritin with renal outcome in chronic kidney disease patients. PLoS One. 2013;7(12):e52775.CrossRef Tsai Y-C, Hung C-C, Kuo M-C, Tsai J-C, Yeh S-M, Hwang S-J, Chiu Y-W, Kuo H-T, Chang J-M, Chen H-C. Association of hsCRP, white blood cell count and ferritin with renal outcome in chronic kidney disease patients. PLoS One. 2013;7(12):e52775.CrossRef
39.
go back to reference Li JH, Luo JF, Jiang Y, Ma YJ, Ji YQ, Zhu GL, Zhou C, Chu HW, Zhang HD. Red blood cell lifespan shortening in patients with early-stage chronic kidney disease. Kidney Blood Pressure Res. 2019;44(5):1158–65.CrossRef Li JH, Luo JF, Jiang Y, Ma YJ, Ji YQ, Zhu GL, Zhou C, Chu HW, Zhang HD. Red blood cell lifespan shortening in patients with early-stage chronic kidney disease. Kidney Blood Pressure Res. 2019;44(5):1158–65.CrossRef
40.
go back to reference Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis. 2004;44(4):715–9.PubMedCrossRef Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis. 2004;44(4):715–9.PubMedCrossRef
41.
go back to reference Sato Y, Mizuguchi T, Shigenaga S, Yoshikawa E, Chujo K, Minakuchi J, Kawashima S. Shortened red blood cell lifespan is related to the dose of erythropoiesis-stimulating agents requirement in patients on hemodialysis. Therapeutic Apheresis Dialysis. 2012;16(6):522–8.PubMedCrossRef Sato Y, Mizuguchi T, Shigenaga S, Yoshikawa E, Chujo K, Minakuchi J, Kawashima S. Shortened red blood cell lifespan is related to the dose of erythropoiesis-stimulating agents requirement in patients on hemodialysis. Therapeutic Apheresis Dialysis. 2012;16(6):522–8.PubMedCrossRef
42.
go back to reference Zhang M, Zhang Y, Li C, He L. Association between red blood cell distribution and renal function in patients with untreated type 2 diabetes mellitus. Ren Fail. 2015;37(4):659–63.PubMedCrossRef Zhang M, Zhang Y, Li C, He L. Association between red blood cell distribution and renal function in patients with untreated type 2 diabetes mellitus. Ren Fail. 2015;37(4):659–63.PubMedCrossRef
43.
go back to reference Zhang J, Cao J, Nie W, Shen H, Hui X. Red cell distribution width is an independent risk factor of patients with renal function damage in type 1 diabetes mellitus of children in China. Ann Clin Lab Sci. 2018;48(2):236–41.PubMed Zhang J, Cao J, Nie W, Shen H, Hui X. Red cell distribution width is an independent risk factor of patients with renal function damage in type 1 diabetes mellitus of children in China. Ann Clin Lab Sci. 2018;48(2):236–41.PubMed
44.
go back to reference Chen C-Y, Lin C-J, Lin C-S, Sun F-J, Pan C-F, Chen H-H, Wu C-J. The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation. Oncotarget. 2017;9(2):2236–48.PubMedPubMedCentralCrossRef Chen C-Y, Lin C-J, Lin C-S, Sun F-J, Pan C-F, Chen H-H, Wu C-J. The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation. Oncotarget. 2017;9(2):2236–48.PubMedPubMedCentralCrossRef
45.
go back to reference Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, Huh W, Paik SW, Ryu S, Chang Y, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8(1):4718.PubMedPubMedCentralCrossRef Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, Huh W, Paik SW, Ryu S, Chang Y, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8(1):4718.PubMedPubMedCentralCrossRef
46.
go back to reference Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: what the Hepatologist should know? Ann Hepatol. 2019;19(2):134–44.PubMedCrossRef Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: what the Hepatologist should know? Ann Hepatol. 2019;19(2):134–44.PubMedCrossRef
Metadata
Title
Baseline liver function tests and full blood count indices and their association with progression of chronic kidney disease and renal outcomes in Aboriginal and Torres Strait Islander people: the eGFR follow- up study
Authors
Sandawana William Majoni
Federica Barzi
Wendy Hoy
Richard J. MacIsaac
Alan Cass
Louise Maple-Brown
Jaquelyne T. Hughes
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2020
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-020-02185-x

Other articles of this Issue 1/2020

BMC Nephrology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine